Blastic plasmacytoid dendritic cell neoplasm with cutaneous presentation: A case series in children.
neoplasm-malignant
skin signs of systemic disease
therapy-systemic
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
pubmed:
23
6
2021
medline:
1
9
2021
entrez:
22
6
2021
Statut:
ppublish
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy that can present with multiorgan involvement including the skin. While this entity accounts for 0.1% of all cutaneous lymphomas in adults, fewer than 90 pediatric cases have been described in the literature. We present three cases of pediatric BPDCN, highlighting the variable cutaneous and clinical presentation.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-886Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Kim MJ, Nasr A, Kabir B, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review. J Pediatr Hematol Oncol. 2017;39(7):528-537.
Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586.
Gambichler T, Pantelaki I, Stücker M. Childhood blastic plasmacytoid dendritic cell neoplasm treated with allogenic stem cell transplantation. Pediatr Dermatol. 2013;30(1):142-144.
Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-1727.
Penney C, Johnston DL, Story E. A unique case of a pediatric patient with blastic plasmacytoid dendritic cell neoplasm, Guillain Barre syndrome, and hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2020;42(5):e392-e393.
Dreyer S, Mednik S, Truong A, et al. Skin lesions serve as clues to relapse of pediatric blastic plasmacytoid dendritic cell neoplasm. Pediatr Dermatol. 2018;35:e132-e135.
Sun W, Liu H, Kim Y, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018;11(1):61.
Nguyen CM, Stuart L, Skupsky H, Lee YS, Tsuchiya A, Cassarino DS. Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: a case series and review of the literature. Am J Dermatopathol. 2015;37(12):924-928.
Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer Discov. 2017;7(2):156-164.
Piccini M, Loscocco G, Gianfaldoni G, et al. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2020;99(4):907-909.
Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
Economides MP, Rizzieri D, Pemmaraju N. Updates in novel therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2019;14(6):515-522.